Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record.

Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial

Fortin, Paul R., Abrahamowicz, Michal, Ferland, Diane, Lacaille, Diane, Smith, C. Douglas, Zummer, Michel, Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus · 2008 · Arthritis Care & Research

Abstract

Objective: To assess the potential benefits of methotrexate in patients with systemic lupus erythematosus (SLE). Methods: A 12‐month, double‐blind, placebo‐controlled trial of methotrexate with folic acid was conducted. Intent‐to‐treat analyses were performed with mixed linear models and α = 0.04 (96% confidence interval [96% CI]) to account for interim analysis of longitudinal data to assess the treatment effects on lupus disease activity and daily steroid dose across monthly measurements, and to test if the treatment effects depended on selected participant characteristics. Results: Of 215 participants screened, 94 were excluded, 35 declined, and 86 were randomized (methotrexate = 41, placebo = 45). The groups were balanced for demographic and disease characteristics. Antimalarial use was more frequent in the placebo group, which was adjusted for in multivariable analyses. Sixty participants (27 methotrexate, 33 placebo) completed the study and 26 terminated early. Among participants who had the same baseline prednisone dose, those taking methotrexate received, on average, 1.33 mg/day less prednisone during the trial period (96% CI 0.06, 2.72 mg/day; a 22% reduction of their average‐during‐trial daily dose) compared with those in the placebo group. For the primary measure of disease activity (revised Systemic Lupus Activity Measure), methotrexate use was also associated with a marginally significant reduction in the mean during‐trial score of 0.86 units (96% CI 0.01, 1.71; P = 0.039). A significant interaction between treatment and baseline damage was found (P = 0.001). Conclusion: Methotrexate conferred a significant advantage in participants with moderately active lupus by lowering daily prednisone dose and slightly decreasing lupus disease activity. As a therapeutic option in moderate SLE, methotrexate can be considered to be steroid sparing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.24068

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Fortin, P. R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C. D., Zummer, M., & Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2008-11-26
Volume
59
Issue
12
Pages
1796-1804
ISSN
  • 0893-7524 (ISSN-L)
  • 1529-0123
OpenAlex
W2016157833
Cited by
165
References
0
FWCI
5.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1002/art.24068
The paper
Fortin, P. R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C. D., Zummer, M., & Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus. (2008). Steroid‐sparing effects of methotrexate in systemic lupus erythematosus: A double‐blind, randomized, placebo‐controlled trial. Arthritis Care & Research. https://doi.org/10.1002/art.24068

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.